<?xml version="1.0" encoding="UTF-8"?>
<p>
 <list list-type="bullet">
  <list-item>
   <p>High sensitivity and specificity assays approaching 100%.</p>
  </list-item>
  <list-item>
   <p>Possibility to combine different methods in one assay enhances detection capability and accuracy (PCR-MS, microfluidic chip technology-based PCR, …).</p>
  </list-item>
  <list-item>
   <p>Automation of the assays reduces the number of operators and manual workload.</p>
  </list-item>
  <list-item>
   <p>Small sample volumes are needed, so the assays can still be performed in particular cases (CSF, new-borns, etc.)</p>
  </list-item>
  <list-item>
   <p>Some assays such as MS remain efficient after several freezing–thawing of the samples (archived samples).</p>
  </list-item>
  <list-item>
   <p>Rapid TAT: minimum time required from sample collection to results reporting is 30 min, and microarray tools can deliver results within seconds.</p>
  </list-item>
  <list-item>
   <p>Low detection limit: 10–100 copies/ml by PCR.</p>
  </list-item>
  <list-item>
   <p>Multiplex reactions: detection of a wide range of pathogens in a single run is time saving.</p>
  </list-item>
  <list-item>
   <p>Detection of rare drug-resistance patterns.</p>
  </list-item>
  <list-item>
   <p>NGS generates many sequencing data per run and sequences long-reads.</p>
  </list-item>
  <list-item>
   <p>Low reaction cost when using microfluidic chips, and use in POC settings.</p>
  </list-item>
  <list-item>
   <p>Lower risk of contamination by processing single tube within one unit.</p>
  </list-item>
 </list>
</p>
